SGS S.A.. (12/7/21). "Press Release: SGS Announces the Acquisition of Quay Pharmaceuticals Limited".

	Organisation	SGS S.A.
	Group	SGS (Group)
	Organisation 2	Quay Pharmaceuticals Ltd. (Quay Pharma)
	Group	SGS (Group)
	Product	drug delivery technology (drug formulation technology)
	Product 2	drug development services
	Index term	Quay Pharmaceuticals–SGS: investment, 202112 acquisition of Quay Pharma by SGS
	Person	Ng, Frankie (SGS –201505–202403 CEO STEPPED DOWN 3/24)
	Person 2	Reeks, Toby (SGS 202012 SVP Investor Relations + Corporate Communciations + Sustainability)

SGS is pleased to welcome into our group Quay Pharmaceuticals Limited (Quay Pharma), a UK-based provider of innovative, formulation research and development services for the global biopharmaceutical sector.

Quay Pharma is a leading innovative Formulation Research and Development Organization with a comprehensive and flexible range of services. It supports its customers through the various stages of pharmaceutical clinical development, from pre-formulation to formulation, dosage form design and optimization. Quay Pharma serves over 150 clients globally and is in the process of opening a new sizeable laboratory on the East Coast of the United States, adding a range of complementary services to Quay Pharma’s existing UK facilities.

Founded in 2002, the company has grown consistently since inception and generated revenues of circa CHF 21 million in the fiscal year ending May 31, 2021. Through the acquisition, SGS welcomes circa 200 highly skilled scientists and technicians to our Health Science group and the current management team will continue to lead the business.

This acquisition represents a meaningful step forward in SGS’s strategy of increasing the scope of services to support our customers across the Health Science supply chain. Quay Pharma will become our global Center of Excellence for Formulation, Research and Development. It adds to our comprehensive portfolio of analytical services, further reinforces our TIC leadership position and enables us to better serve the needs of our global biopharmaceutical customers.

Frankie Ng, CEO of SGS said: “This acquisition supports our strategic evolution by further aligning our global network ever more closely to TIC megatrends. Quay Pharma adds a significant level of competence to the Group and allows us to offer more comprehensive and complex, high value-added services to our customers.”

For further information, please contact:

Toby Reeks
SVP, Corporate Communications, Sustainability & Investor Relations
t: +41 79 641 83 02
www.sgs.com

Ad hoc announcement pursuant to Art. 53 LR

About SGS

We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for quality and integrity. Our 93,000 employees operate a network of 2,600 offices and laboratories, working together to enable a better, safer and more interconnected world.

Record changed: 2023-06-05

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for SGS (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)